Gocovri (amantadine) extended release capsules are approved for the treatment of dyskinesia and/or OFF episodes in levodopa-treated patients with Parkinson’s disease.

We sought to evaluate the effects of Gocovri on patient-perceived disability regarding motor aspects of experiences of daily living as assessed by Part II of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS).

We analyzed changes in MDS-UPDRS Part II total and item scores from baseline to week 12, comparing Gocovri and placebo, using pooled data from phase 3 trials (EASE LID and EASE LID 3).

At week 12, the treatment difference for MDS-UPDRS II total score for Gocovri compared with placebo was −2.0 (P = 0.004), and Gocovri’s change from baseline exceeded a published minimal clinically important difference threshold of 3.05.

Gocovri-treated participants experienced significant improvements in motor aspects of experiences of daily living. Analyses indicated that Gocovri may specifically improve freezing, tremor, getting out of bed/car/deep chair, and eating tasks.